A major strength of our study is the relatively large sample size compared with previous studies. However, our survey-based study is limited by recall bias and a lack of information on the influence of reproductive elements (eg, menarche, menopause) or the use of hormonal contraceptives on the course of HS symptoms. Notwithstanding, the results provide additional clinical relevant insight into the course of symptoms in women with HS.
Interleukin 6 and high-sensitivity C-reactive protein are potential predictive markers of response to infliximab in hidradenitis suppurativa
See related works on pages 54 and 155
To the Editor: The treatment of hidradenitis suppurativa (HS) remains highly challenging. Several studies have shown that antietumor necrosis factor (TNF) antibodies, such as those in infliximab (IFX) or adalimumab, clinically reduce disease activity in some cases of HS. 1 Adalimumab has shown its superiority against placebo in 2 prospective randomized trials. 1 Nevertheless, their efficacy (in this condition) is inconsistent. Identifying predictive markers of response is, thus, of strong interest. The objective of this prospective pilot study was to determine if the baseline inflammatory profile of patients with HS could predict the response to treatment with IFX.
Patients with moderate to severe HS (defined as Hurley stage II or III for at least 6 months) were enrolled, after giving their signed informed consent (institutional review board approval waived), and were treated with IFX (5 mg/kg) on weeks 0, 2, 6, and 14. The serum levels of the following inflammatory cytokines were measured before treatment and before each infusion: TNF-, interleukin (IL)-1, IL-6, and high-sensitivity (hs) C-reactive protein (CRP). All patients were carefully clinically evaluated for other causes that could increase CRP levels and, if Normal values are mean 6 SD; nonnormal values are median (range); qualitative values are number (%). P was calculated using a MannWhitney test. At wk 14, 9 patients reached remission and 4 had worsened disease. Two were underdosed (1 developed Antibodies against IFX). Patients with poor response at the end of the induction phase had a significantly higher level of IL-6 and hs-CRP at diagnosis. There was no difference in sex ratio, age at diagnosis, clinical severity score, TNF-, IL-1 level at diagnosis and trough levels of IFX, or development of antibodies against IFX at wk 14. DLQI, Dermatology Life Quality Index; hs-CRP, high-sensitivity C-reactive protein; IFX, infliximab; IL, interleukin; TNF, tumor necrosis factor; VAS, visual analog scale.
needed, additional biological and radiologic examinations were performed. Clinical evaluation of each patient, at baseline and during treatment, was always performed by the same clinician. The main criterion of IFX efficacy in our patients was the static physician global assessment tool. Disease activity and severity were also assessed using the Hurley score, visual analog pain scale, and Dermatology Life Quality Index (Table I) . [2] [3] [4] Thirteen patients were enrolled and no adverse events were observed, except for 1 patient who developed paradoxical pustular psoriasis. An objective response was observed in 9 patients. We observed worsening of disease in 4 patients, who tended to have the highest Dermatology Life Quality Index score (Table I) . Two patients were underdosed with drug trough levels less than 2 g/mL and 1 of them developed antibodies against IFX (Table I) . High baseline levels of IL-6 and hs-CRP were predictive of nonresponse to IFX (P ¼ .0168 and .0112, respectively, using Mann-Whitney test) (Table II) . Inversely, all patients with IL-6 level below 5 (area under the curve 0.9167; 95% confidence interval 0.7423-1.091; P ¼ .02064) responded to the treatment. The clinical severity score at baseline, IL-1, and TNF-serum levels did not appear as a good predictive markers of response to IFX-therapy (Table II) . A correlation was observed between serum levels of hs-CRP and IL-6 (r ¼ 0.79, P ¼ .0005 using the Pearson correlation test). No similar data were observed with hs-CRP/IL-1 (r ¼ 0.1, P ¼ .74), hs-CRP/TNF (r ¼ 0.12, P ¼ .65), or IL-1/IL-6 (r ¼ 0.01, P ¼ .73). We did not observe any correlation between response to treatment and kinetics of IL-6, hs-CRP, IL-1, and TNF-, with no significant change in their levels during IFX therapy (data not shown).
These results suggest that initial levels of hs-CRP and IL-6 are potential response markers for IFX treatment in HS. Additional studies are needed to determine whether these markers can predict the response to other TNF inhibitors. As there are multiple confounding factors when using CRP levels, 5 it is possible that IL-6 has greater reliability for predicting the response to treatment in patients with HS. Drs Montaudi e and Seitz-Polski contributed equally to this letter.
Intradermal injection of autologous platelet-rich plasma for the treatment of vulvar lichen sclerosus
To the Editor: We designed a pilot study to evaluate the efficacy and safety of autologous platelet-rich plasma (PRP) injections for the treatment of vulvar lichen sclerosus (VLS). After IRB approval was obtained, 15 patients with biopsy proven VLS received 2 separate treatments of PRP separated by 6 weeks. Each treatment consisted of 5 mL of autologous PRP (Magellan Autologous Platelet Separator System, Arteriocyte Medical Systems) injected subdermally and intradermally. A repeat biopsy was performed 6 weeks after the second PRP injection. Patients were not permitted to use additional medications during the trial. The primary efficacy variable, as measured by 2 masked dermatopathologists, was the change in inflammation between the pre-and post-treatment biopsies.
